$SABS
SAB Biotherapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023063076 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $305.0K $1.267M
YoY Change -85.88% -64.69%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $14.88M $2.570M
YoY Change 416.22% -36.45%
% of Gross Profit
Research & Development $4.067M $4.020M
YoY Change -42.26% -45.33%
% of Gross Profit
Depreciation & Amortization $923.2K $960.0K
YoY Change 2.71% 8.45%
% of Gross Profit
Operating Expenses $19.18M $6.590M
YoY Change 91.39% -42.18%
Operating Profit -$5.323M
YoY Change -31.82%
Interest Expense $406.2K $69.70K
YoY Change -2017.71% -1.31%
% of Operating Profit
Other Income/Expense, Net -$4.389M $220.6K
YoY Change -13718.24% -69.83%
Pretax Income -$22.86M -$5.102M
YoY Change 191.21% -27.89%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$22.86M -$5.102M
YoY Change 190.26% -27.89%
Net Earnings / Revenue -7493.77% -402.59%
Basic Earnings Per Share -$0.10
Diluted Earnings Per Share -$3.38 -$0.10
COMMON SHARES
Basic Shares Outstanding 52.32M 52.32M
Diluted Shares Outstanding 52.41M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $56.57M $2.400M
YoY Change 275.93% -71.2%
Cash & Equivalents $56.57M $2.425M
Short-Term Investments
Other Short-Term Assets $2.341M $700.0K
YoY Change 56.68% -22.9%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $58.91M $3.128M
YoY Change 166.58% -85.9%
LONG-TERM ASSETS
Property, Plant & Equipment $24.68M $20.62M
YoY Change 6.16% -14.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $350.2K $400.0K
YoY Change -25.11% -20.22%
Total Long-Term Assets $25.03M $25.21M
YoY Change -13.1% -16.87%
TOTAL ASSETS
Total Short-Term Assets $58.91M $3.128M
Total Long-Term Assets $25.03M $25.21M
Total Assets $83.94M $28.34M
YoY Change 64.9% -46.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $945.9K $1.083M
YoY Change -74.29% -80.25%
Accrued Expenses $7.322M $5.800M
YoY Change -29.31% -48.98%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $1.183M $700.0K
YoY Change 30.64% 321.94%
Total Short-Term Liabilities $10.81M $9.211M
YoY Change -27.88% -46.14%
LONG-TERM LIABILITIES
Long-Term Debt $3.418M $3.500M
YoY Change -18.05% -4.44%
Other Long-Term Liabilities $12.41M $400.0K
YoY Change 1719.22% -64.29%
Total Long-Term Liabilities $15.83M $3.900M
YoY Change 226.13% -18.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.81M $9.211M
Total Long-Term Liabilities $15.83M $3.900M
Total Liabilities $26.64M $13.08M
YoY Change 34.24% -40.23%
SHAREHOLDERS EQUITY
Retained Earnings -$90.10M -$67.20M
YoY Change 88.1% 68.0%
Common Stock $929.00 $5.286K
YoY Change -81.76% 21.29%
Preferred Stock
YoY Change
Treasury Stock (at cost) $5.521M $5.521M
YoY Change 0.0% 0.0%
Treasury Stock Shares
Shareholders Equity $57.30M $15.26M
YoY Change
Total Liabilities & Shareholders Equity $83.94M $28.34M
YoY Change 64.9% -46.03%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$22.86M -$5.102M
YoY Change 190.26% -27.89%
Depreciation, Depletion And Amortization $923.2K $960.0K
YoY Change 2.71% 8.45%
Cash From Operating Activities -$13.45M -$5.170M
YoY Change -6305.89% -36.75%
INVESTING ACTIVITIES
Capital Expenditures $67.15K $90.00K
YoY Change -42.97% -214.65%
Acquisitions
YoY Change
Other Investing Activities $4.450K $40.00K
YoY Change
Cash From Investing Activities -$72.70K -$40.00K
YoY Change -38.26% -49.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 67.63M -140.0K
YoY Change 922.31% 335.19%
NET CHANGE
Cash From Operating Activities -13.45M -5.170M
Cash From Investing Activities -72.70K -40.00K
Cash From Financing Activities 67.63M -140.0K
Net Change In Cash 54.11M -5.350M
YoY Change 705.86% -35.42%
FREE CASH FLOW
Cash From Operating Activities -$13.45M -$5.170M
Capital Expenditures $67.15K $90.00K
Free Cash Flow -$13.52M -$5.260M
YoY Change -13757.23% -35.02%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001833214
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://www.sab.bio/20230930#GrantRevenueMember
CY2022Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://www.sab.bio/20230930#GrantRevenueMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://www.sab.bio/20230930#GrantRevenueMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://www.sab.bio/20230930#GrantRevenueMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39871
dei Entity Registrant Name
EntityRegistrantName
SAB BIOTHERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-3899721
dei Entity Address Address Line1
EntityAddressAddressLine1
2100 East 54th Street North
dei Entity Address City Or Town
EntityAddressCityOrTown
Sioux Falls
dei Entity Address State Or Province
EntityAddressStateOrProvince
SD
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
57104
dei City Area Code
CityAreaCode
605
dei Local Phone Number
LocalPhoneNumber
679-6980
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52319156
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2425480
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15046894
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5556577
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
702231
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1493982
CY2023Q3 us-gaap Assets Current
AssetsCurrent
3127711
CY2022Q4 us-gaap Assets Current
AssetsCurrent
22097453
CY2023Q3 sabs Prepaid Insurance Noncurrent
PrepaidInsuranceNoncurrent
371191
CY2022Q4 sabs Prepaid Insurance Noncurrent
PrepaidInsuranceNoncurrent
467694
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
493473
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1192054
CY2023Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
3722173
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
3896873
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20621749
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23250853
CY2023Q3 us-gaap Assets
Assets
28336297
CY2022Q4 us-gaap Assets
Assets
50904927
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1083169
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3679116
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
541644
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
772665
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
528778
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
490794
CY2023Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
129489
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
132788
CY2023Q3 us-gaap Deferred Income Current
DeferredIncomeCurrent
1627421
CY2022Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
0
CY2023Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
5300442
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
9917981
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
9210943
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14993344
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
361225
CY2023Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
3452442
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
3629642
CY2023Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
417102
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
320930
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
541644
CY2023Q3 us-gaap Liabilities
Liabilities
13080487
CY2022Q4 us-gaap Liabilities
Liabilities
19846785
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
490000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
490000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52865814
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50940920
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52319156
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50394262
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
5286
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
5094
CY2023Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
546658
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
546658
CY2023Q3 us-gaap Treasury Stock Value
TreasuryStockValue
5521246
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
5521246
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
87978548
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
84444049
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-67206778
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47869755
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
15255810
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
31058142
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28336297
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50904927
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1267361
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3589708
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1933980
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21743309
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1267361
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3589708
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1933980
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21743309
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4019718
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7352978
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12217569
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29300405
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2570565
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4044046
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8917960
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13500512
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
6590283
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
11397024
us-gaap Operating Expenses
OperatingExpenses
21135529
us-gaap Operating Expenses
OperatingExpenses
42800917
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5322922
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7807316
us-gaap Operating Income Loss
OperatingIncomeLoss
-19201549
us-gaap Operating Income Loss
OperatingIncomeLoss
-21057608
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-178758
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-782962
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
96172
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-10362614
CY2023Q3 us-gaap Interest Expense
InterestExpense
69700
CY2022Q3 us-gaap Interest Expense
InterestExpense
70626
us-gaap Interest Expense
InterestExpense
237405
us-gaap Interest Expense
InterestExpense
213885
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
14364
CY2022Q3 us-gaap Interest Income Other
InterestIncomeOther
17385
us-gaap Interest Income Other
InterestIncomeOther
100920
us-gaap Interest Income Other
InterestIncomeOther
41143
CY2023Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
97183
CY2022Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1527
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
97183
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1527
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
220605
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
731248
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-135474
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10191399
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5102317
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7076068
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19337023
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10866209
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5102317
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7076068
us-gaap Net Income Loss
NetIncomeLoss
-19337023
us-gaap Net Income Loss
NetIncomeLoss
-10866209
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.1
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.1
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52406002
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52406002
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43030885
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43030885
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51084636
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51084636
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43042379
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43042379
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
31058142
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1890
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
93530
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
602780
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7353820
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
24402522
CY2023Q2 sabs Stock Issued During Period Value Settlement Of Accrued Liabilities
StockIssuedDuringPeriodValueSettlementOfAccruedLiabilities
1550000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
644815
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6880886
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
19716451
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2430
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
639246
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5102317
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
15255810
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
38549913
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
7830
CY2022Q1 sabs Shares Issued Value Forward Purchase Agreement Final Settlement
SharesIssuedValueForwardPurchaseAgreementFinalSettlement
817060
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
897600
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
985863
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
41258266
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
69141
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
569861
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4775996
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
37121272
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
578203
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7076068
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
30623407
us-gaap Net Income Loss
NetIncomeLoss
-19337023
us-gaap Net Income Loss
NetIncomeLoss
-10866209
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2730660
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2270621
sabs Amortization Of Rightofuse Assets
AmortizationOfRightofuseAssets
70221
sabs Amortization Of Rightofuse Assets
AmortizationOfRightofuseAssets
97733
us-gaap Share Based Compensation
ShareBasedCompensation
1886841
us-gaap Share Based Compensation
ShareBasedCompensation
2045664
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
16715
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
15793
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
96172
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-10362614
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
143530
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5556577
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4931330
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-888251
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1227009
sabs Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-394862
sabs Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
75276
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2595947
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1025751
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-2367
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1627421
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-100000
sabs Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-3117538
sabs Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-2217676
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11672688
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21904487
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
44450
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
76390
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
129290
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2048660
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-84840
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1972270
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
772665
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1771746
sabs Payments To Forward Share Purchase Agreement
PaymentsToForwardSharePurchaseAgreement
5521246
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
95541
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
120053
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4320
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
76972
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-863886
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-7336073
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12621414
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-31212830
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15046894
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39545018
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2425480
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8332188
us-gaap Interest Paid Net
InterestPaidNet
179222
us-gaap Interest Paid Net
InterestPaidNet
143259
sabs Issuance Of Common Stock Settlement Of Accrued Liabilities Value
IssuanceOfCommonStockSettlementOfAccruedLiabilitiesValue
1500000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) Nature of Business</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SAB Biotherapeutics, Inc., a Delaware corporation (“SAB” or “SAB Biotherapeutics”, and together with its subsidiaries, the “Company”), is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. SAB’s novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine™) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses. However, SAB’s platform is the first to produce fully human antibodies in large animals.</span></p><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Australian Research and Development Tax Credit</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2023, the Company formed a new subsidiary in Australia, SAB BIO PTY LTD, a proprietary limited company (“SAB Australia”), primarily to conduct preclinical and clinical activities for product candidates. SAB Australia’s research and development activities qualify for the Australian government’s tax credit program, which provides a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43.5</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% credit for qualifying research and development expenses. The Company expects to commence a Phase 1 trial in the fourth quarter of 2023.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited condensed financial statements have been prepared assuming the Company will continue as a going concern, which contemplates continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has experienced net losses, negative cash flows from operations and, as of September 30, 2023, had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67.2</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company anticipates to continue to generate losses for the foreseeable future and expects the losses to increase as the Company continues the development of, or seeks regulatory approvals for product candidates, and begins commercialization of products. As a result, the Company will require additional capital to fund operations in order to support long-term plans.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 29, 2023, the Company entered into a securities purchase agreement with certain accredited investors (the “September 2023 Purchase Agreement”), pursuant to which the Company agreed to issue and</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> sell shares of preferred stock and warrants, in a private placement which provides for up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">110</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in proceeds across multiple tranches. Between October 2023 and November 2023, the Company received an aggregate of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67.1</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for shares of preferred stock issued in this private placement offering. </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Note 17, </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Subsequent Events</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for further information about the private placement offering.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company will need to raise additional capital to fund its operations, to continue to execute its strategy and to continue as a going concern. The Company plans to seek additional funding through a combination of equity or debt financings, or other third-party financing, collaborative or other funding arrangements. Should the Company seek additional financing from outside sources, the Company may not be able to raise such financing on terms acceptable to the Company or at all. If the Company is unable to raise additional capital when required or on acceptable terms, the Company may be required to scale back or discontinue the advancement of product candidates, reduce headcount, liquidate assets, file for bankruptcy, reorganize, merge with another entity, or cease operations.</span></p>
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-67200000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the financial statements. The Company has used significant estimates in its determination of stock-based compensation assumptions, determination of the fair value of the Company’s common stock prior to becoming a public company, determination of the fair value of the Company’s warrants, determination of the incremental borrowing rate (“IBR”) used in the calculation of the Company’s right of use assets and lease liabilities, the valuation allowance on deferred tax assets, and research and development expenses related to clinical trial accruals. Actual amounts realized may differ from these estimates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of credit risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Although the Company currently believes that the financial institutions with whom it does business will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so. The Company has not experienced any credit losses associated with its balances in such accounts for the nine months ended September 30, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
CY2023Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5102317
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7076068
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19337023
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10866209
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52406002
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52406002
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43030885
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43030885
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51084636
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51084636
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43042379
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43042379
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.1
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.1
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26927025
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18963445
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26874905
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20139961
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
29611117
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
29529375
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8989368
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6278522
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20621749
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23250853
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
960000
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
890000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2730000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2270000
CY2023Q3 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
us-gaap Acquisition Costs
AcquisitionCosts
5000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y10M6D
CY2023Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P15Y2M1D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0677
CY2023Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0772
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
174721
CY2023Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
100374
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
368320
CY2023Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
401496
CY2023Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
401496
CY2023Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
401496
CY2023Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
401496
CY2023Q3 sabs Finance Lease Liability Payments Due After Year Four
FinanceLeaseLiabilityPaymentsDueAfterYearFour
4382998
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
543041
CY2023Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
6089356
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
14263
CY2023Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
2507425
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
528778
CY2023Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
3581931
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
528778
CY2023Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
129489
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2023Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
3452442
CY2023Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
22000
CY2022Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
25000
CY2023Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
70000
CY2022Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
71000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
70000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
98000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
210000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
214000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
118000
CY2023Q3 sabs Finance Lease Payments
FinanceLeasePayments
100000
us-gaap Operating Lease Payments
OperatingLeasePayments
354000
sabs Finance Lease Payments
FinanceLeasePayments
306000
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
309000
CY2022Q3 sabs Finance Lease Payments
FinanceLeasePayments
103000
us-gaap Operating Lease Payments
OperatingLeasePayments
930000
sabs Finance Lease Payments
FinanceLeasePayments
334000
CY2023Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
694236
CY2022Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
511849
CY2023Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
172371
CY2022Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
357390
CY2023Q3 sabs Accrued Constructionin Progress Current
AccruedConstructioninProgressCurrent
0
CY2022Q4 sabs Accrued Constructionin Progress Current
AccruedConstructioninProgressCurrent
85767
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
15930
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
186833
CY2023Q3 sabs Accrued Clinical Trial Expense
AccruedClinicalTrialExpense
117918
CY2022Q4 sabs Accrued Clinical Trial Expense
AccruedClinicalTrialExpense
355479
CY2023Q3 sabs Accrued Outside Lab Services
AccruedOutsideLabServices
279857
CY2022Q4 sabs Accrued Outside Lab Services
AccruedOutsideLabServices
1106903
CY2023Q3 sabs Accrued Bonus And Severance
AccruedBonusAndSeverance
0
CY2022Q4 sabs Accrued Bonus And Severance
AccruedBonusAndSeverance
950324
CY2023Q3 sabs Accrued Contract Manufacturing
AccruedContractManufacturing
0
CY2022Q4 sabs Accrued Contract Manufacturing
AccruedContractManufacturing
25129
CY2023Q3 sabs Accrued Legal
AccruedLegal
803255
CY2022Q4 sabs Accrued Legal
AccruedLegal
856505
CY2023Q3 sabs Accrued Financing Fees Payable
AccruedFinancingFeesPayable
2910500
CY2022Q4 sabs Accrued Financing Fees Payable
AccruedFinancingFeesPayable
4910500
CY2023Q3 sabs Accrued Franchise Tax Payable
AccruedFranchiseTaxPayable
30000
CY2022Q4 sabs Accrued Franchise Tax Payable
AccruedFranchiseTaxPayable
50000
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
66375
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
8192
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
210000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
513110
CY2023Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
5300442
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
9917981
CY2023Q3 sabs Insurance Policy Premiums Financed Value
InsurancePolicyPremiumsFinancedValue
1200000
CY2023Q3 sabs Insurance Policy Premiums Financed Interest Rate
InsurancePolicyPremiumsFinancedInterestRate
0.0547
CY2023Q3 sabs Insurance Financing Note Payable
InsuranceFinancingNotePayable
0
CY2022Q4 sabs Insurance Financing Note Payable
InsuranceFinancingNotePayable
773000
CY2023Q3 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
500000000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
490000000
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
sabs Earnout Shares At Fair Value
EarnoutSharesAtFairValue
12000000
sabs Earnout Value At Fair Value
EarnoutValueAtFairValue
101300000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7095462
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.99
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M14D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
109891
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2911750
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.57
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
40409
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.99
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
8000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.54
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
137574
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
2.06
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9821229
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.57
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y4M28D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
437894
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
5049015
sabs Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Vestedand Exercisable
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageVestedandExercisable
1.97
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P3Y9M
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
193470
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3600000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M20D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.57
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
619104
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
108611
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.41
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.78
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
924715
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
314380
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.974
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.802
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.819
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.78
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.974
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.974
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.817
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.941
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0355
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0356
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.035
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.039
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0138
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0356
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
639246
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
578203
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1886841
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2045664
CY2023Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P3Y21D
CY2022Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P3Y9M21D
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.002
us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4100000
CY2023Q3 sabs Related Party Transactions Beneficial Owners Percentage
RelatedPartyTransactionsBeneficialOwnersPercentage
0.05
CY2023Q3 sabs Related Party Transactions Ownership Interest Percentage
RelatedPartyTransactionsOwnershipInterestPercentage
0.05
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.03
CY2023Q3 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
71000
CY2022Q3 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
91000
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
211000
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
350000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
490000000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
sabs-20230930_cal.xml Edgar Link unprocessable
0000950170-23-063076-index-headers.html Edgar Link pending
0000950170-23-063076-index.html Edgar Link pending
0000950170-23-063076.txt Edgar Link pending
0000950170-23-063076-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sabs-20230930.htm Edgar Link pending
sabs-20230930.xsd Edgar Link pending
sabs-ex31_1.htm Edgar Link pending
sabs-ex31_2.htm Edgar Link pending
sabs-ex32_1.htm Edgar Link pending
sabs-ex32_2.htm Edgar Link pending
Show.js Edgar Link pending
sabs-20230930_def.xml Edgar Link unprocessable
sabs-20230930_lab.xml Edgar Link unprocessable
sabs-20230930_pre.xml Edgar Link unprocessable
sabs-20230930_htm.xml Edgar Link completed